Premium
Molecular basis for the antiandrogen withdrawal syndrome
Author(s) -
Miyamoto Hiroshi,
Rahman Mujib M.,
Chang Chawnshang
Publication year - 2003
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.10757
Subject(s) - antiandrogen , blockade , discontinuation , prostate cancer , androgen receptor , androgen , medicine , signal transduction , endocrinology , cancer research , oncology , bioinformatics , receptor , cancer , biology , hormone , genetics
Abstract In patients with prostate cancer who manifest disease progression during combined androgen blockade therapy, discontinuation of antiandrogen treatment might result in prostate‐specific antigen decline, often associated with clinical improvement. The response called antiandrogen withdrawal syndrome is thus acknowledged as a general phenomenon. However, molecular mechanisms responsible for this syndrome are not completely understood. This article outlines the proposed mechanisms, including alterations of androgen receptor gene and its coregulatory proteins and activation of the signal transduction pathway, and the potential therapeutic approaches based on the specific mechanisms. © 2003 Wiley‐Liss, Inc.